Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Alicia N Stein, Catherine G A Pendrey, David J Muscatello, Paul G Van Buynder, James E Fielding, Jason C Menche, Sheena G Sullivan
BACKGROUND: The interpretation of relative vaccine effectiveness (rVE) of improved influenza vaccines is complex. Estimation of burden averted is useful to contextualise their potential impact across different seasons. For the population aged under 65 years in Australia, this study estimated the additional morbidity and mortality that could be averted using improved influenza vaccines. METHODS: We used observed, season-specific (2015-2019) influenza notification and influenza-coded hospitalisation frequencies and published modelled estimates of influenza-associated hospitalisations and deaths that occurred under the prevailing influenza vaccination coverage scenario...
April 2024: Influenza and Other Respiratory Viruses
#22
JOURNAL ARTICLE
Rebekah Honce, Ana Vazquez-Pagan, Brandi Livingston, Alexandra H Mandarano, Benjamin A Wilander, Sean Cherry, Virginia Hargest, Bridgett Sharp, Pamela H Brigleb, Ericka Kirkpatrick Roubidoux, Lee-Ann Van de Velde, R Chris Skinner, Maureen A McGargill, Paul G Thomas, Stacey Schultz-Cherry
Metabolic disease is epidemiologically linked to severe complications upon influenza virus infection, thus vaccination is a priority in this high-risk population. Yet, vaccine responses are less effective in these same hosts. Here we examined how the timing of diet switching from a high-fat diet to a control diet affected influenza vaccine efficacy in diet-induced obese mice. Our results demonstrate that the systemic meta-inflammation generated by high-fat diet exposure limited T cell maturation to the memory compartment at the time of vaccination, impacting the recall of effector memory T cells upon viral challenge...
April 18, 2024: Nature Microbiology
#23
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: Lower respiratory infections (LRIs) are a major global contributor to morbidity and mortality. In 2020-21, non-pharmaceutical interventions associated with the COVID-19 pandemic reduced not only the transmission of SARS-CoV-2, but also the transmission of other LRI pathogens. Tracking LRI incidence and mortality, as well as the pathogens responsible, can guide health-system responses and funding priorities to reduce future burden. We present estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 of the burden of non-COVID-19 LRIs and corresponding aetiologies from 1990 to 2021, inclusive of pandemic effects on the incidence and mortality of select respiratory viruses, globally, regionally, and for 204 countries and territories...
April 15, 2024: Lancet Infectious Diseases
#24
JOURNAL ARTICLE
Z Beau Reneer, Harrison C Bergeron, Stephen Reynolds, Elena Thornhill-Wadolowski, Lan Feng, Marcin Bugno, Agnieszka D Truax, Ralph A Tripp
Influenza viruses cause epidemics and can cause pandemics with substantial morbidity with some mortality every year. Seasonal influenza vaccines have incomplete effectiveness and elicit a narrow antibody response that often does not protect against mutations occurring in influenza viruses. Thus, various vaccine approaches have been investigated to improve safety and efficacy. Here, we evaluate an mRNA influenza vaccine encoding hemagglutinin (HA) proteins in a BALB/c mouse model. The results show that mRNA vaccination elicits neutralizing and serum antibodies to each influenza virus strain contained in the current quadrivalent vaccine that is designed to protect against four different influenza viruses including two influenza A viruses (IAV) and two influenza B (IBV), as well as several antigenically distinct influenza virus strains in both hemagglutination inhibition assay (HAI) and virus neutralization assays...
2024: PloS One
#25
JOURNAL ARTICLE
Özge Özgen-Top, Pınar Aysert-Yıldız, Hasan Selçuk Özger, Özlem Güzel-Tunçcan
OBJECTIVE: Influenza is among the most important respiratory infections affecting all age groups and can lead to hospitalizations. We aimed to determine the frequency of influenza infections among acute admissions with influenza-like illness (ILI) and evaluate the demographic, clinical findings, and outcomes of patients with influenza. METHODS: This prospective, active surveillance study was conducted in a university hospital between 2015 and 2017. Patients hospitalized for at least 24 hours in the selected units with community-acquired ILI were screened according to certain influenza-predicting ICD-10 codes...
December 2023: Infect Dis Clin Microbiol
#26
REVIEW
Erika Petro-Turnquist, Matthew J Pekarek, Eric A Weaver
Swine Influenza A Virus (IAV-S) imposes a significant impact on the pork industry and has been deemed a significant threat to global public health due to its zoonotic potential. The most effective method of preventing IAV-S is vaccination. While there are tremendous efforts to control and prevent IAV-S in vulnerable swine populations, there are considerable challenges in developing a broadly protective vaccine against IAV-S. These challenges include the consistent diversification of IAV-S, increasing the strength and breadth of adaptive immune responses elicited by vaccination, interfering maternal antibody responses, and the induction of vaccine-associated enhanced respiratory disease after vaccination...
2024: Frontiers in Cellular and Infection Microbiology
#27
JOURNAL ARTICLE
Hüseyin Bilgin, Tuğçe Başarı, Nazlı Pazar, Işıl Küçüker, Rabia Can-Sarınoğlu
OBJECTIVE: This study aimed to compare 28-day mortality between patients have hospital-acquired influenza (HAI) and those have community-acquired influenza (CAI) during the 2017-2019 influenza seasons in a tertiary care center in İstanbul, Türkiye. MATERIALS AND METHODS: This retrospective cohort included all hospitalized patients who had confirmed influenza infection and were over 17 years old. HAI was defined as a case of influenza that tested negative in a PCR test or had no signs of influenza on admission but with a positive test result at any point after 72 hours of admission...
September 2023: Infect Dis Clin Microbiol
#28
JOURNAL ARTICLE
Diana Diaz-Cánova, Ugo Moens, Annika Brinkmann, Andreas Nitsche, Malachy Ifeanyi Okeke
Modified vaccinia virus Ankara (MVA) has been widely tested in clinical trials as recombinant vector vaccine against infectious diseases and cancers in humans and animals. However, one biosafety concern about the use of MVA vectored vaccine is the potential for MVA to recombine with naturally occurring orthopoxviruses in cells and hosts in which it multiplies poorly and, therefore, producing viruses with mosaic genomes with altered genetic and phenotypic properties. We previously conducted co-infection and superinfection experiments with MVA vectored influenza vaccine (MVA-HANP) and a feline Cowpox virus (CPXV-No-F1) in Vero cells (that were semi-permissive to MVA infection) and showed that recombination occurred in both co-infected and superinfected cells...
2024: Frontiers in Immunology
#29
JOURNAL ARTICLE
Ahmed S Atwa, Lamis Gomaa, Wael Elmenofy, Haitham M Amer, Basem M Ahmed
BACKGROUND: Equine influenza (EI) is a transmissible viral respiratory sickness of the Equidae family. Two viruses, H7N7 and H3N8 caused EI; however, H7N7 has not been detected for decades. H3N8 has circulated and bifurcated into Eurasian and American lineages. The latter subsequently diversified into Kentucky, South America, and Florida sub-lineages. Florida clade 1 (FC1) and Florida clade 2 (FC2) strains are the only circulating EI viruses (EIVs) in the meantime. Immunization is considered the major means for the prevention and control of EI infection...
January 2024: Open Veterinary Journal
#30
JOURNAL ARTICLE
Juan Alvarado, Keval Yerigeri, Anita Boakye, Christina Randolph, Aparna Roy, Grace Onimoe
COVID-19 infection has been a significant contributor to global morbidity and mortality, especially among those patients with chronic diseases. The Centers for Disease Control and Prevention have classified sickle cell disease (SCD) as a condition that increases the risk of severe illness from COVID-19 infection. A retrospective study was conducted using the TRiNetX health research network database to identify SCA patients ( HbSS, Sbeta-thalassemia zero) who had SARS-CoV-2 infection over 2 years; these were compared with similar patients who did not have the infection in terms of demographics, pain control, and laboratory parameters COVID-19 illness impacts [ain crises and ACS, and prior vaccination against influenza and COVID-19 may represent a protective factor for developing pain crises...
April 2024: EJHaem
#31
REVIEW
Xiaojian Zhang, Ted M Ross
INTRODUCTION: Anti-neuraminidase (NA) immunity correlates with the protection against influenza virus infection in both human and animal models. The aim of this review is to better understand the mechanism of anti-NA immunity, and also to evaluate the approaches on developing NA-based influenza vaccines or enhancing immune responses against NA for current influenza vaccines. AREAS COVERED: In this review, the structure of influenza neuraminidase, the contribution of anti-NA immunity to protection, as well as the efforts and challenges of targeting the immune responses to NA were discussed...
April 17, 2024: Expert Review of Vaccines
#32
JOURNAL ARTICLE
Simon van der Pol, Florian Zeevat, Maarten J Postma, Cornelis Boersma
OBJECTIVES: We assess the cost-effectiveness of switching from standard-dose quadrivalent influenza vaccination (SD-QIV) to high-dose vaccination (HD-QIV) for Dutch adults aged 60 years and older. METHODS: A health-economic model was used to compare the scenario where HD-QIV was implemented compared to the current standard, SD-QIV. This model used a lifetime horizon and assessed the cost-effectiveness from a societal perspective. A recently published meta-analysis was used to incorporate the benefits of HD-QIV, including cardiorespiratory hospitalizations, in analyses considering RCT only or combining RCT and RWE estimates in a scenario analysis...
April 17, 2024: Vaccine
#33
JOURNAL ARTICLE
Sung-Mok Jung, Sara L Loo, Emily Howerton, Lucie Contamin, Claire P Smith, Erica C Carcelén, Katie Yan, Samantha J Bents, John Levander, Jessi Espino, Joseph C Lemaitre, Koji Sato, Clifton D McKee, Alison L Hill, Matteo Chinazzi, Jessica T Davis, Kunpeng Mu, Alessandro Vespignani, Erik T Rosenstrom, Sebastian A Rodriguez-Cartes, Julie S Ivy, Maria E Mayorga, Julie L Swann, Guido España, Sean Cavany, Sean M Moore, T Alex Perkins, Shi Chen, Rajib Paul, Daniel Janies, Jean-Claude Thill, Ajitesh Srivastava, Majd Al Aawar, Kaiming Bi, Shraddha Ramdas Bandekar, Anass Bouchnita, Spencer J Fox, Lauren Ancel Meyers, Przemyslaw Porebski, Srini Venkatramanan, Aniruddha Adiga, Benjamin Hurt, Brian Klahn, Joseph Outten, Jiangzhuo Chen, Henning Mortveit, Amanda Wilson, Stefan Hoops, Parantapa Bhattacharya, Dustin Machi, Anil Vullikanti, Bryan Lewis, Madhav Marathe, Harry Hochheiser, Michael C Runge, Katriona Shea, Shaun Truelove, Cécile Viboud, Justin Lessler
BACKGROUND: Coronavirus Disease 2019 (COVID-19) continues to cause significant hospitalizations and deaths in the United States. Its continued burden and the impact of annually reformulated vaccines remain unclear. Here, we present projections of COVID-19 hospitalizations and deaths in the United States for the next 2 years under 2 plausible assumptions about immune escape (20% per year and 50% per year) and 3 possible CDC recommendations for the use of annually reformulated vaccines (no recommendation, vaccination for those aged 65 years and over, vaccination for all eligible age groups based on FDA approval)...
April 17, 2024: PLoS Medicine
#34
JOURNAL ARTICLE
Gang Chen, Qingxia Han, Wan-Xiang Li, Rong Hai, Shou-Wei Ding
Global control of infectious diseases depends on the continuous development and deployment of diverse vaccination strategies. Currently available live-attenuated and killed virus vaccines typically take a week or longer to activate specific protection by the adaptive immunity. The mosquito-transmitted Nodamura virus (NoV) is attenuated in mice by mutations that prevent expression of the B2 viral suppressor of RNA interference (VSR) and consequently, drastically enhance in vivo production of the virus-targeting small-interfering RNAs...
April 23, 2024: Proceedings of the National Academy of Sciences of the United States of America
#35
JOURNAL ARTICLE
Tasnim Hasan, Michelle Lynch, Catherine King, Charbel Wehbe, Martin Plymoth, Md Saiful Islam, Theodore Iannuzzi, Aiken Dao, Jana Lai, Alexandra Martiniuk, Shalini Desai, Meru Sheel
BACKGROUND: Outbreaks of vaccine preventable diseases (VPDs) in health care workers (HCWs) can result in morbidity and mortality and cause significant disruptions to health care services, patients and visitors as well as an added burden on the health system. This scoping review is aimed to describe the epidemiology of VPD outbreaks in HCW, caused by diseases which are prevented by the ten vaccines recommended by World Health Organization (WHO) for HCWs. METHODS: In April 2022 CINAHL, MEDLINE, Global Health and EMBASE were searched for all articles reporting on VPD outbreaks in HCWs since the year 2000...
April 17, 2024: Clinical Infectious Diseases
#36
JOURNAL ARTICLE
Rosa Sloot, Alexander Breskin, Lisandro D Colantonio, Andrew G Allmon, Ying Yu, Swati Sakhuja, Ligong Chen, Paul Muntner, M Alan Brookhart, Nafeesa Dhalwani
BACKGROUND: Initiation of proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9 mAb) for lipid-lowering following myocardial infarction (MI) is likely affected by patients' prognostic factors, potentially leading to bias when comparing real-world treatment effects. METHODS: Using target-trial emulation, we assessed potential confounding when comparing two treatment strategies post-MI: initiation of PCSK9 mAb within 1 year and no initiation of PCSK9 mAb...
March 12, 2024: Epidemiology
#37
JOURNAL ARTICLE
Juliette Bougon, Eileigh Kadijk, Lucie Gallot-Lavallee, Bruce A Curtis, Matthew Landers, John M Archibald, Denys A Khaperskyy
Many viruses inhibit general host gene expression to limit innate immune responses and gain preferential access to the cellular translational apparatus for their protein synthesis. This process is known as host shutoff. Influenza A viruses (IAVs) encode two host shutoff proteins: nonstructural protein 1 (NS1) and polymerase acidic X (PA-X). NS1 inhibits host nuclear pre-messenger RNA maturation and export, and PA-X is an endoribonuclease that preferentially cleaves host spliced nuclear and cytoplasmic messenger RNAs...
April 17, 2024: Journal of Virology
#38
JOURNAL ARTICLE
Yujie Hou, Guohua Deng, Pengfei Cui, Xianying Zeng, Bin Li, Dongxue Wang, Xinwen He, Cheng Yan, Yaping Zhang, Jiongjie Li, Jinming Ma, Yanbing Li, Xiurong Wang, Guobin Tian, Huihui Kong, Lijie Tang, Yasuo Suzuki, Jianzhong Shi, Hualan Chen
Human infections with the H7N9 influenza virus have been eliminated in China through vaccination of poultry; however, the H7N9 virus has not yet been eradicated from poultry. Carefully analysis of H7N9 viruses in poultry that have sub-optimal immunity may provide a unique opportunity to witness the evolution of highly pathogenic avian influenza virus in the context of vaccination. Between January 2020 and June 2023, we isolated 16 H7N9 viruses from samples we collected during surveillance and samples that were sent to us for disease diagnosis...
April 17, 2024: Emerging Microbes & Infections
#39
JOURNAL ARTICLE
Lucie Chastaingt, Marie Laure Toba, Carine Boulon, Loubna Dari, Joel Constans, Hela Daoud, Romain Chauvet, Caroline Adou, Julien Magne, Philippe Lacroix
<b/> Background: In the latest American Heart Association guidelines, influenza vaccination is recommended for patients with peripheral arterial disease (PAD). The vaccination coverage in this specific population is currently unknown. This study aims to determine the adherence to influenza vaccination in a PAD population and identify associated determinants. Patients and methods. Hospitalized patients and outpatients with PAD from two university departments of vascular medicine were prospectively included...
April 17, 2024: VASA. Zeitschrift Für Gefässkrankheiten
#40
JOURNAL ARTICLE
Jose L Martínez, Nicholas Lemus, Tsoi Ying Lai, Mitali Mishra, Irene González-Domínguez, Eduard Puente-Massaguer, Madhumathi Loganathan, Benjamin Francis, Marie I Samanovic, Florian Krammer, Mark J Mulligan, Viviana Simon, Peter Palese, Weina Sun
The head domain of the hemagglutinin of influenza viruses plays a dominant role in the antibody response due to the presence of immunodominant antigenic sites that are the main targets of host neutralizing antibodies. For the H1 hemagglutinin, five major antigenic sites defined as Sa, Sb, Ca1, Ca2, and Cb have been described. Although previous studies have focused on defining the hierarchy of the antigenic sites of the hemagglutinin in different human cohorts, it is still unclear if the immunodominance profile of the antigenic sites might change with the antibody levels of individuals or if other demographic factors (such as exposure history, sex, or age) could also influence the importance of the antigenic sites...
April 15, 2024: Vaccine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
